Key Takeaways:
- The 2025 ACR Manual on Contrast Media replaces the old GBCA classification system with three distinct groups based on NSF risk, with gadopiclenol receiving a provisional Group III designation.
- Routine eGFR screening before contrast administration is no longer universal – targeted screening now applies only to patients with specific renal risk factors.
- Pregnancy and breastfeeding protocols have been significantly relaxed: routine screening before iodinated contrast is now considered unnecessary, breastfeeding cessation is no longer recommended, and pregnancy screening remains recommended before gadolinium-based contrast administration.
- CMS permanently codified virtual direct supervision beginning January 1, 2026 – a change that reshapes how imaging facilities can staff compliant contrast exams without an on-site radiologist.
- Tightened documentation requirements mean facilities need audit-ready records that capture supervision method, timing, contrast details, and adverse event data.
The 2025 ACR Manual on Contrast Media is not a minor refresh. For radiologists and imaging facility managers, it reshapes daily workflows around GBCA selection, renal function screening, documentation, and special population protocols.
Three GBCA Groups Now Replace the Old System
The previous GBCA classification framework has been retired. In its place, the ACR Manual establishes a cleaner, evidence-driven three-group structure organized around nephrogenic systemic fibrosis (NSF) risk. NSF is a rare but serious fibrotic condition that can develop in patients with severely compromised renal function who receive certain gadolinium-based contrast agents.
The new structure gives clinicians a clearer decision framework – particularly when selecting agents for patients with renal comorbidities. Each group carries distinct risk implications, precaution requirements, and documentation considerations. Understanding where each agent falls is now a baseline competency for anyone involved in contrast-enhanced imaging.
What Changed in NSF Risk Classification
Group I: Highest-Risk Agents with FDA Contraindications
Group I agents carry the greatest historical burden of NSF cases and come with FDA contraindications for high-risk patients. This group includes gadodiamide (Omniscan), gadopentetate dimeglumine (Magnevist), and gadoversetamide (OptiMARK). Patients contraindicated for these agents include those on any form of dialysis, those with severe or end-stage CKD (Stage 4 or 5, eGFR <30 mL/min/1.73 m²), and those with acute kidney injury (AKI).
Group II: Low-to-Nonexistent NSF Risk
Group II is the most populated category and includes gadobenate dimeglumine (MultiHance), gadobutrol (Gadavist), gadoteric acid (Dotarem, Clariscan), gadoteridol (ProHance), gadopiclenol (Elucirem, Vueway), and gadoxetate disodium (Eovist/Primovist). The ACR Committee considers NSF risk from these agents sufficiently low – or possibly nonexistent – at standard doses, meaning that renal function assessment before intravenous administration is optional, not required.
The manual also introduces the concept of “GBCA burden” – the cumulative lifetime gadolinium dose – as a consideration for patients who require repeated contrast-enhanced MRI studies. This is not yet a hard protocol trigger, but it signals that longitudinal tracking is becoming part of responsible GBCA stewardship.
Group III: Gadopiclenol’s Provisional Status
Gadopiclenol (Elucirem, Vueway) receives a provisional Group III designation in the manual, separate from its Group II listing, reflecting an ongoing evaluation of its unique safety profile. This dual positioning acknowledges that while the agent appears low-risk, its post-market evidence base is still accumulating. Facilities using gadopiclenol should track ACR updates as this classification is subject to revision.
CA-AKI Screening Is No Longer Universal
One of the most operationally significant changes in the manual is the shift away from routine eGFR testing for all contrast patients. The terminology itself has evolved: Contrast-Induced Nephropathy (CIN) has been replaced by Contrast-Associated Acute Kidney Injury (CA-AKI) – a broader term that acknowledges kidney injury following contrast administration without assuming the contrast was the cause. The more specific term, Contrast-Induced AKI (CI-AKI), is reserved for injury directly attributable to contrast media.
Who Still Needs eGFR Testing
Targeted screening now applies to patients with a documented history of renal disease – including known CKD, prior AKI, dialysis, kidney transplant, single kidney, renal surgery or cancer, or albuminuria. Diabetes, particularly when combined with other renal risk factors or when the patient is on metformin, is a consideration that may prompt targeted eGFR screening. Patients on metformin should also be assessed for temporary discontinuation needs.
Routine intravascular study patients without any of these risk factors no longer require a baseline eGFR. Current evidence supports that patients with eGFR ≥30 mL/min/1.73 m² are not at increased risk of CI-AKI from intravenous iodinated contrast. The threshold for heightened concern is eGFR <30 mL/min/1.73 m² or the presence of AKI.
Hydration Guidance for Confirmed High-Risk Patients
For patients who meet high-risk criteria (eGFR <30 mL/min/1.73 m² or AKI), IV volume expansion remains the primary prevention strategy. The manual recommends isotonic fluids - typically 0.9% normal saline - beginning one hour before the exam and continuing 3-12 hours after, with longer regimens (~12 hours) showing better outcomes. Dosing may be weight-based at 1-3 mL/kg per hour.
Prophylaxis is not indicated for the general population with stable eGFR ≥30 mL/min/1.73 m², or for patients on chronic dialysis. For the eGFR 30-44 mL/min/1.73 m² range, prophylaxis may be considered case-by-case at the ordering provider’s discretion.
Revised Rules for Special Populations
Pregnancy and Breastfeeding
The new guidelines explicitly state that radiologists should not routinely screen for pregnancy before iodinated contrast administration in women of childbearing age, and should not withhold contrast when it is clinically indicated. Pregnancy screening remains recommended before gadolinium-based contrast administration. While iodinated contrast does cross the placenta, in vivo animal studies show no mutagenic or teratogenic effects from low-osmolality agents.
For breastfeeding, cessation is no longer recommended for either iodinated or gadolinium-based contrast agents. Infant systemic exposure through breast milk is minimal, and continued breastfeeding is considered safe.
Pediatric and Geriatric Patients
Pediatric contrast dosing is individualized based on patient weight and clinical context. Special attention applies to neonates and infants in the first three weeks of life, where plasma creatinine reflects maternal levels and cannot be used reliably to assess renal function.
For older adults, advanced age alone is not classified as an independent risk factor for contrast reactions or CA-AKI. The manual recommends individualizing protocols based on overall clinical status – with attention to polypharmacy, hydration, and comorbidity burden – rather than chronological age.
Documentation Requirements Have Tightened
The ACR Manual places renewed emphasis on thorough, standardized documentation across the contrast administration workflow. Required elements include pre-procedure risk factor assessment, contrast agent type and volume administered, and any adverse reactions observed. Routine post-procedure creatinine measurement is not recommended for patients with normal baseline kidney function. For patients with eGFR <30 mL/min/1.73 m² or AKI who do receive contrast, follow-up renal assessment may be appropriate.
Facilities undergoing ACR accreditation will be evaluated on compliance with current published guidelines – making documentation a clinical and operational responsibility.
Virtual Supervision Meets CMS and ACR Requirements
Beginning January 1, 2026, CMS permanently codified virtual direct supervision as part of the Calendar Year 2026 Medicare Physician Fee Schedule Final Rule. Supervising physicians are no longer required to be physically present in the same office suite. Instead, they can meet the “immediately available” standard through real-time, two-way audio and video technology – a permanent change that removes previous frequency restrictions in inpatient hospitals, skilled nursing facilities, and critical care settings.
What Qualifies as Compliant Remote Supervision
The compliance bar is specific. The supervising physician must be available via live video and live audio simultaneously throughout the service. Audio-only communication – a standard phone call, for example – does not meet CMS criteria and will result in claim denial. The technology must support real-time two-way visual and verbal communication with no exceptions.
Audit-Ready Documentation Your Team Must Capture
CMS and OIG continue to list incident-to billing among top audit targets. Expanded virtual supervision access does not reduce scrutiny – if anything, it increases it. Clinical staff should document the following explicitly in the EHR:
- Method of supervision – state “live video/audio” directly; “I was available” is not sufficient.
- Timestamps – document when supervision began, that it was continuous, and when it ended.
- Practice location enrollment – confirm all locations providing telehealth services are correctly enrolled in Medicare.
Practices should audit incident-to billing documentation before the next billing cycle and train all supervising physicians on the specific EHR language required.
Keeping Operations Compliant
Managing evolving ACR standards is straightforward on paper – but operationally, it requires trained personnel, consistent protocols, and documentation infrastructure that holds up to scrutiny. Virtual supervision providers like ContrastConnect address this by providing radiologist-supervised contrast coverage through a secure, HIPAA-compliant virtual platform.
These platforms are built for audit-ready documentation aligned with both ACR and CMS requirements, technologist training on updated protocols, and standardized emergency response procedures. For imaging networks facing radiologist shortages or multi-site compliance challenges, that kind of infrastructure removes the need to hire, train, and retain on-site radiologists at every location.
ContrastConnect
Las vegas
Las Vegas
NV
89109
United States
